Abstract:
Lepidium sativum of the Brassicaceae family, is used to treat inflammatory conditions such as
arthritis. The purpose of this study is to evaluate the in vivo anti-inflammatory activity of the
Lepidium sativum seed hydromethanolic extract on the model of acute inflammation of the
mouse foot edema induced by Carragenan. And to confirm anti-inflammatory activity a
histophatological study was carried out at the end of the experiment. The acute toxicity
assessed on mice showed that the hydromethanolic extract of Lepidium sativum seeds
produced no toxic effects at 300 mg/kg body weight. NMRI mice were selected and
experiments were conducted in three groups, the therapeutic dose group (150 and 300mg/kg),
the standard group and the control group. In the 1% Carragenan-induced leg edema, the test
extract produced moderate anti-inflammatory activity, the percentage inhibition of edema
volume with the 300mg/kg extract tested and Diclofenac (50mg/kg) at the 5th hour was
86.85% and 83.49%, respectively. As a result, the anti-inflammatory effect of the Lepidium
sativum seed hydromethanolic extract appears to be more effective than that of standard
(Diclofenac). However, the effect did not show statistically significant activity due to the
variation in standard group data. A histophatological study carried out on the skin tissue of the
mouse paw confirms the anti-inflammatory effect of the hydromethanolic extract of the seeds
of Lepidium sativum.
